Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Sinovac Quadrivalent Influenza Vaccine in Healthy Infants
NCT05245552Phase 3Completed
- Sponsor
- Sinovac Biotech Ltd.
- Start
- Aug 2022
- Primary completion
- Aug 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of quadrivalent influenza vaccine in seasonal influenza, sponsored by Sinovac Biotech Ltd.. Started Aug 2022; status: completed.
02
Drugs
quadrivalent influenza vaccine
03
Conditions
seasonal influenza
Beyond the preview
Go deeper on NCT05245552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05245552.